Sarclisa (isatuximab-irfc) for the Treatment of Multiple Myeloma
Sarclisa is an anti-CD3 monoclonal antibody that attacks multiple myeloma cancer cells. Credit: Sanofi-Aventis.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more